YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) trades at $0.55 with AI Score 50/100 (Grade B). YiChang HEC ChangJiang Pharmaceutical Co. , Ltd. Market cap: $643.13M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for YIHCF: YIHCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates YIHCF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
YIHCF: the 1 perspectives are evenly split.
How is this calculated? →YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) Healthcare & Pipeline Overview
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops and distributes pharmaceutical products in China, focusing on anti-viral, endocrine, metabolic, and cardiovascular disease treatments. With a high dividend yield and strategic partnerships, the company aims to expand its market presence in the Chinese healthcare sector amidst competition from both domestic and international players.
What Is the Investment Thesis for YIHCF?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. presents a mixed investment case. The company's high dividend yield of 10.32% may attract income-focused investors. A P/E ratio of 25.0 suggests moderate valuation relative to earnings. The company's focus on key therapeutic areas like anti-viral and cardiovascular diseases aligns with growing healthcare needs in China. Strategic partnerships, such as the collaboration with Alibaba Health Technology, could drive future growth. However, the company faces competition in the generic drug market and regulatory hurdles typical of the pharmaceutical industry. Investors should carefully weigh these factors.
Based on FMP financials and quantitative analysis
YIHCF Key Highlights
- Market Cap of $643.13M reflects the company's current valuation in the OTC market.
- P/E Ratio of 25.0 indicates the price investors are willing to pay for each dollar of earnings.
- Profit Margin of 13.0% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 75.0% highlights efficient production and pricing strategies.
- Dividend Yield of 10.32% provides a substantial return to shareholders, potentially attracting income-seeking investors.
Who Are YIHCF's Competitors?
YIHCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABSCF AB Science S.A. | $1.12 | +0.00% | $78.15M | 55 |
| AGYTF Allergy Therapeutics plc | $0.15 | +7.14% | $756.30M | 59 |
| BOIRF Boiron S.A. | $31.50 | +5.00% | $546.91M | 43 |
| BPMUF Basilea Pharmaceutica AG | $60.27 | +0.00% | $746.00M | 58 |
| ELTP Elite Pharmaceuticals, Inc. | $0.36 | +6.41% | $393.14M | 53 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are YIHCF's Key Strengths?
- Focus on high-demand therapeutic areas.
- Established distribution network in China.
- Strategic partnerships with key industry players.
- Manufacturing capabilities for both drugs and APIs.
What Are YIHCF's Weaknesses?
- Reliance on distributors for sales.
- Potential pricing pressures in the generic drug market.
- Dependence on regulatory approvals for new products.
- Limited geographic diversification outside of China.
What Could Drive YIHCF Stock Higher?
- Potential regulatory approvals for new drugs in the pipeline could drive revenue growth.
- Strategic partnerships with Alibaba Health Technology and other companies may lead to increased market access and sales.
- Growing demand for pharmaceutical products in China due to an aging population and increasing healthcare spending.
- Expansion of the company's product line in key therapeutic areas.
What Are the Key Risks for YIHCF?
- Increased competition from domestic and international pharmaceutical companies.
- Changes in government regulations and healthcare policies could impact the company's business.
- Pricing pressures from generic drug manufacturers may reduce profit margins.
- Dependence on distributors for sales could limit control over market access.
- Risks associated with investing in OTC stocks, including limited liquidity and regulatory oversight.
What Are the Growth Opportunities for YIHCF?
- Expanding Anti-Viral Product Line: The company's collaboration with Alibaba Health Technology on influenza projects represents a significant growth opportunity. With the global anti-viral drug market projected to reach $50 billion by 2028, YiChang HEC ChangJiang Pharmaceutical can leverage this partnership to develop and market innovative anti-viral treatments, capturing a share of this expanding market. Success hinges on the timely development and approval of new drugs, as well as effective marketing and distribution strategies.
- Penetrating the Endocrine and Metabolic Disease Market: Given the rising prevalence of diabetes and other metabolic disorders in China, YiChang HEC ChangJiang Pharmaceutical's focus on this therapeutic area offers substantial growth potential. The Chinese market for diabetes treatments alone is projected to reach $20 billion by 2027. The company can capitalize on this trend by expanding its product portfolio and strengthening its distribution network to reach a wider patient base.
- Strengthening Cardiovascular Disease Product Offerings: Cardiovascular diseases are a leading cause of death in China, creating a large and growing market for related treatments. YiChang HEC ChangJiang Pharmaceutical can enhance its market position by investing in research and development of new cardiovascular drugs, as well as expanding its existing product line. The market for cardiovascular drugs in China is expected to reach $15 billion by 2025, presenting a significant opportunity for the company.
- Leveraging Strategic Partnerships for Market Access: YiChang HEC ChangJiang Pharmaceutical's partnerships with Jointown Pharmaceutical Group Co., Ltd. and China National Accord Medicines Corporation Ltd. provide access to extensive distribution networks across China. By leveraging these partnerships, the company can expand its reach to hospitals and medical institutions, increasing sales and market share. The effectiveness of this strategy depends on maintaining strong relationships with its partners and ensuring efficient supply chain management.
- Investing in Research and Development for Innovative Drugs: To maintain a competitive edge, YiChang HEC ChangJiang Pharmaceutical must continue to invest in research and development of innovative drugs and medical devices. This includes exploring new therapeutic targets, developing novel drug delivery systems, and conducting clinical trials to demonstrate the efficacy and safety of its products. Successful innovation will allow the company to differentiate itself from competitors and capture higher profit margins.
What Opportunities Does YIHCF Have?
- Expanding product line in existing therapeutic areas.
- Entering new therapeutic areas with unmet needs.
- Increasing market share through strategic partnerships.
- Expanding into international markets.
What Threats Does YIHCF Face?
- Increased competition from domestic and international players.
- Changes in government regulations and healthcare policies.
- Pricing pressures from generic drug manufacturers.
- Patent expirations and the emergence of biosimilars.
What Are YIHCF's Competitive Advantages?
- Established distribution network in China.
- Strategic partnerships with key players in the healthcare industry.
- Focus on specific therapeutic areas with high demand.
- Manufacturing capabilities for both finished drugs and APIs.
What Does YIHCF Do?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd., established in 2001 and based in Yichang, China, is a pharmaceutical company dedicated to the development, manufacture, and sale of pharmaceutical products. The company's therapeutic focus spans anti-virus, endocrine and metabolic diseases, and cardiovascular diseases, addressing critical healthcare needs within the People's Republic of China. Beyond finished drugs, YiChang HEC ChangJiang Pharmaceutical also manufactures and sells active pharmaceutical ingredients (APIs), contributing to the broader pharmaceutical supply chain. The company actively engages in research and development of medical devices, drugs, and biotechnology, signaling a commitment to innovation and future growth. YiChang HEC ChangJiang Pharmaceutical distributes its products to hospitals and medical institutions through a well-established network of distributors. Strategic collaborations are integral to the company's growth strategy, including partnerships with Alibaba Health Technology (China) Limited for influenza projects, Jointown Pharmaceutical Group Co., Ltd., Guangdong Yihao Pharmaceutical Co., Ltd., Shenzhen HEC Industrial Development Co., Ltd, and China National Accord Medicines Corporation Ltd. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
What Products and Services Does YIHCF Offer?
- Develops pharmaceutical products targeting anti-viral treatments.
- Manufactures drugs for endocrine and metabolic diseases.
- Produces medications for cardiovascular diseases.
- Sells active pharmaceutical ingredients (APIs).
- Researches and develops medical devices and drugs.
- Provides medical consulting services.
- Engages in biotechnology research and development.
How Does YIHCF Make Money?
- Develops and manufactures pharmaceutical products.
- Sells products to hospitals and medical institutions through distributors.
- Generates revenue through the sale of pharmaceutical products and APIs.
- Partners with other companies for distribution and research collaborations.
What Industry Does YIHCF Operate In?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. operates within China's pharmaceutical industry, a sector experiencing growth driven by an aging population and increasing healthcare spending. The market is competitive, with both domestic and international players vying for market share. The company's focus on generic drugs places it in a segment subject to pricing pressures and regulatory scrutiny. Strategic partnerships and a focus on specific therapeutic areas are crucial for differentiation and growth in this landscape. The Chinese pharmaceutical market is expected to continue expanding, presenting both opportunities and challenges for companies like YiChang HEC ChangJiang Pharmaceutical.
Who Are YIHCF's Key Customers?
- Hospitals and medical institutions in China.
- Patients requiring treatments for anti-viral, endocrine, metabolic, and cardiovascular diseases.
- Pharmaceutical companies that purchase APIs.
FY2026 estForward Outlook
Wall Street analysts project YiChang HEC ChangJiang Pharmaceutical Co., Ltd. revenue of about $4.48B for fiscal 2026, with EPS near $1.66.
ROE 6%Key Financial Metrics
Return on equity for YiChang HEC ChangJiang Pharmaceutical Co., Ltd. stands at 5.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.9%, showing how much profit it generates from its asset base. YIHCF trades at a trailing price-to-earnings ratio of 24.99, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is -9.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.77 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.10 places it in the safe zone, indicating low near-term bankruptcy risk.
YIHCF Valuation & Market Position
With a $643.13M market cap, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. sits in the small-cap segment of the market. Relative to its peer group, YIHCF's quantitative score of 50/100 is roughly in line with the peer average of 54/100.
YIHCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Focus on high-demand therapeutic areas.
- Established distribution network in China.
- Strategic partnerships with key industry players.
- Manufacturing capabilities for both drugs and APIs.
Bear Case
- Reliance on distributors for sales.
- Potential pricing pressures in the generic drug market.
- Dependence on regulatory approvals for new products.
- Limited geographic diversification outside of China.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
YIHCF Latest News
No recent news available for YIHCF.
YIHCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for YIHCF.
Price Targets
Wall Street price target analysis for YIHCF.
YIHCF MoonshotScore
What does this score mean?
The MoonshotScore rates YIHCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Juncai Jiang
CEO
Juncai Jiang serves as the CEO of YiChang HEC ChangJiang Pharmaceutical Co., Ltd., overseeing the operations of a company with over 4,600 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic development and market expansion. He has been instrumental in forging key partnerships and driving the company's growth in the Chinese market. His leadership emphasizes innovation and quality in pharmaceutical development.
Track Record: Under Juncai Jiang's leadership, YiChang HEC ChangJiang Pharmaceutical has expanded its product portfolio and strengthened its market position in key therapeutic areas. He has overseen the establishment of strategic collaborations, including the partnership with Alibaba Health Technology. His tenure has been marked by a focus on research and development, contributing to the company's pipeline of innovative drugs.
YIHCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that YiChang HEC ChangJiang Pharmaceutical Co., Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries higher risks compared to those listed on major exchanges due to the potential for less regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity compared to major exchanges.
- Less stringent regulatory oversight and disclosure requirements.
- Potential for higher price volatility.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor trading activity and price movements.
- Established partnerships with reputable companies like Alibaba Health Technology.
- Focus on developing and manufacturing pharmaceutical products in key therapeutic areas.
- Presence in the Chinese pharmaceutical market.
- Operational history since 2001.
- Subsidiary of Guangdong HEC Technology Holding Co., Ltd.
What Investors Ask About YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) — Healthcare
What does YiChang HEC ChangJiang Pharmaceutical Co., Ltd. do?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that develops, manufactures, and sells a range of pharmaceutical products. Its primary focus is on therapeutic areas including anti-viral, endocrine and metabolic diseases, and cardiovascular diseases. The company also manufactures and sells active pharmaceutical ingredients (APIs). They distribute their products to hospitals and medical institutions throughout China via a network of distributors and strategic partnerships, including a collaboration with Alibaba Health Technology for influenza-related projects.
What do analysts say about YIHCF stock?
Analyst coverage of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) is limited due to its OTC listing. Key valuation metrics include a P/E ratio of 25.0 and a high dividend yield of 10.32%. Growth considerations revolve around the company's ability to expand its product line, leverage strategic partnerships, and navigate the competitive landscape of the Chinese pharmaceutical market. The company's financial performance and growth prospects should be carefully evaluated.
What are the main risks for YIHCF?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. faces several risks, including intense competition from both domestic and international pharmaceutical companies in China. Pricing pressures in the generic drug market could impact profit margins. Regulatory changes and healthcare policy shifts in China could also affect the company's business. Additionally, as an OTC-listed stock, YIHCF carries risks associated with limited liquidity, less stringent regulatory oversight, and potential price volatility.
What are the key factors to evaluate for YIHCF?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) holds an AI score of 50/100 (moderate). P/E: 25.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does YIHCF data refresh on this page?
YIHCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven YIHCF's recent stock price performance?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-demand therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider YIHCF overvalued or undervalued right now?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) trades at 25.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying YIHCF?
Before investing in YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- AI analysis pending for YIHCF.